title: Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens.
abstract: Ingestion of thalidomide was associated with a reduction in the upregulation of the granulocyte activation marker CD11b and a reduced capacity to release elastase and lactoferrin after stimulation with lipopolysaccharide or lipoteichoic acid. A single oral dose of thalidomide attenuates neutrophil activation upon ex vivo stimulation with bacterial antigens.
authors: Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: N P
authors: NP
authors: Juffermans
authors: A
authors: A
authors: Verbon
authors: M J
authors: MJ
authors: Schultz
authors: C E
authors: CE
authors: Hack
authors: S J
authors: SJ
authors: van Deventer
authors: P
authors: P
authors: Speelman
authors: T
authors: T
authors: van der Poll
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000942:Antigens, Bacterial / Q000494:pharmacology*; D004347:Drug Interactions; D006098:Granulocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007781:Lactoferrin / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D016177:Macrophage-1 Antigen / Q000378:metabolism*; D018375:Neutrophil Activation / Q000187:drug effects*; D010196:Pancreatic Elastase / Q000378:metabolism; D013792:Thalidomide / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D000942:Antigens, Bacterial; D008070:Lipopolysaccharides; D016177:Macrophage-1 Antigen; D013792:Thalidomide; D007781:Lactoferrin; D010196:Pancreatic Elastase